PT-141 Nasal Spray

The intranasal route is where PT-141 was originally investigated before development moved to a parenteral presentation, which makes this the format closest to the earliest published work on the molecule. Supplied as a pre-mixed solution in an amber bottle with a metered pump: approximately 0.1 ml per actuation and approximately 100 actuations available, with no reconstitution step and no syringe measurement. Concentration is fixed at manufacture, so this format supports repeat-actuation protocols rather than dose-ranging designs, for which the lyophilised vial is the appropriate choice. Prime before the first counted actuation, store at 2-8°C, keep upright and capped, and log the opening date. For research purposes only, not for human consumption.

Purity

99%+

Physical Form

Nasal spray solution

Bottle Size

10mg

Storage

2-8°C

Appearance

Clear solution in an amber metered-spray bottle

Volume Per Actuation

Approximately 0.1 ml per actuation

Metered Actuations

Approximately 100 metered actuations per bottle

Handling

Prime before first use, keep the bottle upright and capped between actuations

Studied in the context of

• The intranasal route is where PT-141 was originally investigated before development moved to a parenteral presentation, which makes this the format closest to the earliest published work on the molecule.
• Supplied as a pre-mixed solution in an amber bottle with a metered pump: approximately 0.1 ml per actuation and approximately 100 actuations available, with no reconstitution step and no syringe measurement.
• Concentration is fixed at manufacture, so this format supports repeat-actuation protocols rather than dose-ranging designs, for which the lyophilised vial is the appropriate choice.
• Prime before the first counted actuation, store at 2-8°C, keep upright and capped, and log the opening date.